Missed GME or NVDA? Donโt Miss the Next One.โ
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
ACTU Stock Forecast 2025-2026
$8.95
Current Price
$176.57M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ACTU Price Targets
+134.6%
To High Target of $21.00
+123.5%
To Median Target of $20.00
+123.5%
To Low Target of $20.00
ACTU Price Momentum
+6.9%
1 Week Change
+13.3%
1 Month Change
0.0%
1 Year Change
+12.4%
Year-to-Date Change
-23.7%
From 52W High of $11.73
+62.4%
From 52W Low of $5.51
๐ MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Actuate Therapeutics (ACTU) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ACTU and similar high-potential opportunities.
Latest ACTU Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, ACTU has a bullish consensus with a median price target of $20.00 (ranging from $20.00 to $21.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $8.95, the median forecast implies a 123.5% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Swayampakula Ramakanth at HC Wainwright & Co., suggesting a 123.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACTU Analyst Ratings
3
Buy
0
Hold
0
Sell
ACTU Price Target Range
Low
$20.00
Average
$20.00
High
$21.00
Current: $8.95
Latest ACTU Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACTU.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 17, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Initiates | $20.00 |
Actuate Therapeutics Inc. (ACTU) Competitors
The following stocks are similar to Actuate Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Actuate Therapeutics Inc. (ACTU) Financial Data
Actuate Therapeutics Inc. has a market capitalization of $176.57M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -26,189.1%.
Valuation Metrics
Market Cap
$176.57M
Enterprise Value
$166.17M
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+4.9%
Current Ratio
1.0x
Debt/Equity
0.0x
ROE
-26,189.1%
ROA
-255.4%
๐ฐ DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Actuate Therapeutics Inc. (ACTU) Business Model
About Actuate Therapeutics Inc.
What They Do
Develops innovative therapies for serious diseases.
Business Model
Actuate Therapeutics Inc. operates by advancing clinical trials and research for its unique therapeutic candidates targeting serious diseases such as cancer and inflammatory conditions. The company generates revenue through the commercialization of its therapies once they successfully complete clinical trials and receive regulatory approval.
Additional Information
The company focuses on targeting disease pathways associated with cancer and chronic inflammation, which positions it favorably in the healthcare and biotechnology sectors. Actuate Therapeutics is poised to make significant contributions to medical advancements and improve patient outcomes through its innovative drug development efforts.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
10
CEO
Mr. Daniel M. Schmitt
Country
United States
IPO Year
N/A
Website
actuatetherapeutics.comActuate Therapeutics Inc. (ACTU) Latest News & Analysis
Latest News
Quick Summary
An oral presentation at ASCO will showcase topline Phase 2 data for elraglusib combined with gemcitabine/nab-paclitaxel in treating metastatic pancreatic ductal adenocarcinoma.
Why It Matters
Positive Phase 2 data on elraglusib combined with GnP for mPDAC could indicate potential market opportunities, affecting stock prices and investor sentiment in biotech firms.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Actuate Therapeutics (NASDAQ: ACTU) will present data on elraglusib for advanced salivary gland carcinoma at the AACR Annual Meeting 2025, April 25-30 in Chicago. Abstracts will be published online.
Why It Matters
Actuate Therapeutics' presentation of elraglusib data at a major cancer conference could drive investor interest and stock volatility, reflecting the company's potential in treating challenging cancers.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Actuate Therapeutics, Inc. (NASDAQ: ACTU) will have CEO Daniel Schmitt participate in upcoming investor conferences, focusing on therapies targeting difficult-to-treat cancers via GSK-3ฮฒ inhibition.
Why It Matters
CEO Daniel Schmitt's participation in investor conferences signals potential growth opportunities and transparency for Actuate Therapeutics, which may attract investor interest and impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Actuate Therapeutics announced positive results from its Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel for metastatic pancreatic cancer, indicating potential progress in treatment options.
Why It Matters
Positive trial results for Actuate's elraglusib combined with GnP in treating mPDAC could lead to increased investor confidence, potential market approval, and higher stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Actuate Therapeutics, Inc. (NASDAQ: ACTU) will participate in a webinar hosted by Lantern Pharma on October 30, 2024, focusing on its cancer treatment developments.
Why It Matters
Actuate Therapeutics' participation in a prominent webinar may enhance visibility and investor interest, potentially impacting stock performance and investment decisions in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Actuate Therapeutics (NASDAQ: ACTU) updated on its Phase 1/2 trial of elraglusib for relapsed/refractory Ewing Sarcoma, targeting difficult-to-treat cancers through GSK-3ฮฒ inhibition.
Why It Matters
Updates on clinical trials can influence stock prices, as positive results may indicate potential market success, while setbacks can lead to declines. Ewing Sarcoma's treatment developments affect investor sentiment and valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ACTU Stock
What is Actuate Therapeutics Inc.'s (ACTU) stock forecast for 2025?
Based on our analysis of 1 Wall Street analysts, Actuate Therapeutics Inc. (ACTU) has a median price target of $20.00. The highest price target is $21.00 and the lowest is $20.00.
Is ACTU stock a good investment in 2025?
According to current analyst ratings, ACTU has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.95. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACTU stock?
Wall Street analysts predict ACTU stock could reach $20.00 in the next 12 months. This represents a 123.5% increase from the current price of $8.95. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Actuate Therapeutics Inc.'s business model?
Actuate Therapeutics Inc. operates by advancing clinical trials and research for its unique therapeutic candidates targeting serious diseases such as cancer and inflammatory conditions. The company generates revenue through the commercialization of its therapies once they successfully complete clinical trials and receive regulatory approval.
What is the highest forecasted price for ACTU Actuate Therapeutics Inc.?
The highest price target for ACTU is $21.00 from at , which represents a 134.6% increase from the current price of $8.95.
What is the lowest forecasted price for ACTU Actuate Therapeutics Inc.?
The lowest price target for ACTU is $20.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 123.5% increase from the current price of $8.95.
What is the overall ACTU consensus from analysts for Actuate Therapeutics Inc.?
The overall analyst consensus for ACTU is bullish. Out of 1 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are ACTU stock price projections?
Stock price projections, including those for Actuate Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 9:15 AM UTC